Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Short Interest Update

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) was the recipient of a large growth in short interest during the month of June. As of June 15th, there was short interest totaling 73,164 shares, a growth of 87.5% from the May 31st total of 39,018 shares. Approximately 10.5% of the shares of the stock are sold short. Based on an average trading volume of 362,400 shares, the days-to-cover ratio is presently 0.2 days.

Lakewood-Amedex Biotherapeutics Price Performance

NASDAQ:LABT traded up $0.16 during mid-day trading on Wednesday, hitting $3.30. 297,245 shares of the company’s stock traded hands, compared to its average volume of 292,000. The stock has a fifty day moving average of $12.90. Lakewood-Amedex Biotherapeutics has a twelve month low of $2.95 and a twelve month high of $98.20.

Analyst Ratings Changes

Separately, Wall Street Zen lowered shares of Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th.

About Lakewood-Amedex Biotherapeutics

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.